Preview Mode Links will not work in preview mode

Howard G. Smith, M.D. is a former radio medical editor and talk show host in the Boston Metro area. His "Medical Minute" of health and wellness news and commentary was a regular weekday feature on WBZ-AM, WRKO-AM, and WMRE-AM. His popular two-way talk show, Dr. Howard Smith OnCall, was regularly heard Sunday morning and middays on WBZ.

Dr. Smith has adopted audio and video podcasting as conduits for HEALTH NEWS YOU SHOULD USE. Based on the latest medical, health, and wellness literature these reports provide practical information you can use to keep yourself and your family healthy. Many reports have video versions, and Dr. Smith’s YouTube Channel may be found at:

Trained at Harvard Medical School and a long-time faculty member at Boston Children’s Hospital, he practiced Pediatric Otolaryngology for 40 years in Boston, Southern California, and in central Connecticut.  He is now based in New York City.

If you have questions or suggestions about this content, please email the doctor at or leave him a message at 516-778-8864.  His website is:

Please note that the news, views, commentary, and opinions that Dr. Smith provides are for informational purposes only. Any changes that you or members of your family contemplate making to lifestyle, diet, medications, or medical therapy should always be discussed beforehand with personal physicians who have been supervising your care.

Nov 19, 2020




The FDA just granted an emergency use authorization, the prized EUA, for Lilly’s IgG1 monoclonal antibody called Bamlanivimab.  This now joins the  Regeneron dual antibody cocktail as early treatment for CoVid.


Thing is, though, there are many catch-22s about bamlanivimab.  It must be given immediately after symptom onset when patients are at their most contagious and a danger to others.  It’s not for hospitalized patients or for those requiring oxygen.  Bamlanivimab requires 3 hours for IV infusion, its tricky to prepare and requires refrigeration, and it has serious side effects like anaphylaxis.  The worst problem: it’s in short supply and there’s only about 2 week’s worth in existence.


#covid #bamlanivimab #monoclonalantibody